Program
rusfertide
Also written as “PTG-300”, “Rusfertide” and “Open-label rusfertide”.
Its studies are mostly in Polycythemia Vera · Thalassemia · Hemochromatosis, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Protagonist Therapeutics | 82 open or running | phase 3since Jan 14, 2022 | Jan 9, 2019 | none ahead |
| Takeda | 22 open or running | phase 2since Jun 10, 2026 | Jun 10, 2026 | Oct 28, 2027phase 2 · NCT07648030 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 9, 2019First study: phase 2 study in β-thalassemiaNew to Protagonist TherapeuticsProtagonist Therapeutics · NCT03802201 · 63 enrolled · United States, Greece, Italy and more
- Aug 7, 20192 phase 2 studiesProtagonist Therapeutics · NCT04057040, NCT04054921
- Dec 16, 2019Phase 2 study in HemochromatosisProtagonist Therapeutics · NCT04202965 · 16 enrolled · United States, Canada
- Aug 10, 2020Phase 1 study in Healthy VolunteersProtagonist Therapeutics · NCT04516382 · 12 enrolled · Australia
- Feb 18, 2021Phase 2 study in Polycythemia VeraProtagonist Therapeutics · NCT04767802 · 20 enrolled · Korea, Republic of, Malaysia
- Jan 14, 2022Phase 3 study in Polycythemia VeraProtagonist Therapeutics · NCT05210790 · 293 enrolled · United States, Australia, Austria and more
- Sep 5, 2023Phase 3 study in Polycythemia VeraProtagonist Therapeutics · NCT06033586 · 46 enrolled · United States
- Jun 10, 2026Takeda's first study: phase 2 study in Polycythemia VeraNew to TakedaTakeda · NCT07648030 · 9 planned · Japan
- Aug 11, 2026Phase 2 study in Polycythemia VeraTakeda · NCT07765602 · 24 planned
Ahead
- Oct 28, 2027Primary completion: phase 2 study in Polycythemia VeraTakeda · NCT07648030
- Jul 1, 2028Primary completion: phase 2 study in Polycythemia VeraTakeda · NCT07765602
TargetBeta
“An injectable peptide mimetic of hepcidin (hepcidin antimicrobial peptide; HAMP; putative liver tumor regressor; PLTR; liver-expressed antimicrobial peptide 1; LEAP-1) ”NCIt, by rule
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07765602Polycythemia Vera | 2 | Not yet recruiting | Takeda | Jul 1, 2028 | 24 |
| NCT07648030Polycythemia Vera · Japan | 2 | Recruiting | Takeda | Oct 28, 2027 | 9 |
| NCT06033586Polycythemia Vera · United States | 3 | Active, not recruiting | Protagonist Therapeutics | Apr 1, 2026 | 46 |
| NCT05210790Polycythemia Vera · United States, Australia, Austria and more | 3 | Active, not recruiting | Protagonist Therapeutics | Feb 21, 2025 | 293 |
| NCT04767802Polycythemia Vera · Korea, Republic of, Malaysia | 2 | Completed | Protagonist Therapeutics | Mar 15, 2023 | 20 |
| NCT04516382Healthy Volunteers · Australia | 1 | Completed | Protagonist Therapeutics | Jan 12, 2021 | 12 |
| NCT04202965Hemochromatosis · United States, Canada | 2 | Completed | Protagonist Therapeutics | Oct 6, 2021 | 16 |
| NCT04054921β-thalassemia · United States, Greece, Lebanon and more | 2 | Completed | Protagonist Therapeutics | Jul 31, 2020 | 34 |
| NCT04057040Polycythemia Vera · United States, India | 2 | Completed | Protagonist Therapeutics | Feb 14, 2023 | 70 |
| NCT03802201β-thalassemia · United States, Greece, Italy and more | 2 | Completed | Protagonist Therapeutics | Jul 31, 2020 | 63 |
How it is read
Names in the registry
- “PTG-300”, 6 entries
- “Rusfertide”, 3 entries
- “Open-label rusfertide”, 1 entry
Conditions, from the studies’ own filings
- Polycythemia Vera, 6 studies
- Thalassemia, 2 studies
- Hemochromatosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.